Description

ELDAPRIL 10 MG

Indications

ELDAPRIL 10 MG, containing the active ingredient lisinopril, is primarily indicated for the treatment of hypertension (high blood pressure) in adults and children aged 6 years and older. It is also used to manage heart failure, either alone or in conjunction with other medications, and to improve survival after a heart attack (myocardial infarction). Additionally, ELDAPRIL may be prescribed for the treatment of diabetic nephropathy in patients with type 1 diabetes.

Mechanism of Action

Lisinopril, the active component of ELDAPRIL, is an angiotensin-converting enzyme (ACE) inhibitor. It works by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. By reducing the levels of angiotensin II, lisinopril leads to vasodilation, which decreases blood pressure and reduces the workload on the heart. This mechanism also contributes to the reduction of fluid retention and the prevention of kidney damage in diabetic patients.

Pharmacological Properties

ELDAPRIL exhibits a rapid absorption profile, with peak plasma concentrations typically reached within 7 hours after oral administration. The bioavailability of lisinopril is approximately 25%, and it is not significantly affected by food intake. The drug is primarily excreted unchanged in the urine, making renal function an important consideration in dosing. The half-life of lisinopril is approximately 12 hours, allowing for once-daily dosing in most patients.

Contraindications

ELDAPRIL is contraindicated in patients with a known hypersensitivity to lisinopril or any other ACE inhibitors. It should not be used during pregnancy due to the risk of fetal harm, particularly in the second and third trimesters. Additionally, ELDAPRIL is contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy and in those with severe renal impairment or aortic stenosis.

Side Effects

Common side effects of ELDAPRIL may include dizziness, headache, fatigue, and cough. More serious adverse effects can occur, such as hyperkalemia (elevated potassium levels), hypotension (low blood pressure), renal impairment, and angioedema (swelling of the face, lips, throat, or tongue). Patients should be monitored for these side effects, especially during the initiation of therapy or when the dosage is adjusted.

Dosage and Administration

The recommended starting dose of ELDAPRIL for adults with hypertension is typically 10 mg once daily. Depending on the patient’s response, the dose may be adjusted to a maximum of 40 mg per day. For heart failure, the initial dose is usually 5 mg once daily, with potential titration based on tolerance and clinical response. In pediatric patients aged 6 years and older, the dosing is weight-based, typically starting at 0.07 mg/kg once daily, not exceeding 5 mg per day. It is essential to monitor blood pressure and renal function regularly during treatment.

Interactions

ELDAPRIL may interact with several other medications. Nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce the antihypertensive effect of lisinopril and may increase the risk of renal impairment. Concurrent use of potassium-sparing diuretics or potassium supplements can lead to hyperkalemia. Additionally, the risk of hypotension may be increased when ELDAPRIL is used with other antihypertensive agents. Patients should inform their healthcare provider of all medications, including over-the-counter drugs and supplements, to avoid potential interactions.

Precautions

Before starting ELDAPRIL, a thorough medical history should be taken, particularly regarding renal function, electrolyte levels, and history of angioedema. Caution is advised in patients with renal artery stenosis, as ACE inhibitors can exacerbate renal impairment in these individuals. Elderly patients may be more sensitive to the effects of ELDAPRIL, necessitating careful monitoring and possible dose adjustments. It is also crucial to monitor blood pressure regularly, especially after initiating therapy or adjusting the dose.

Clinical Studies

Clinical studies have demonstrated the efficacy of ELDAPRIL in reducing blood pressure and improving cardiovascular outcomes. In a randomized controlled trial, patients treated with lisinopril showed significant reductions in systolic and diastolic blood pressure compared to placebo. Furthermore, studies have indicated that lisinopril can improve survival rates in patients post-myocardial infarction and reduce the progression of diabetic nephropathy. Long-term studies have also shown that lisinopril effectively manages heart failure symptoms and improves quality of life.

Conclusion

ELDAPRIL 10 MG is a well-established medication for the management of hypertension, heart failure, and post-myocardial infarction care. Its mechanism of action as an ACE inhibitor provides significant cardiovascular benefits and renal protection, particularly in diabetic patients. While generally well-tolerated, it is important for healthcare providers to monitor patients for potential side effects and interactions with other medications. ELDAPRIL has a robust clinical profile, supported by numerous studies demonstrating its efficacy and safety.